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license (http://creativecommons.org/Summary Background/Objective: Advanced synthetic biomaterials that are able to reduce
or replace the need for autologous bone transplantation are still a major clinical need in ortho-
paedics, dentistry, and trauma. Key requirements for improved bone substitutes are optimal
handling properties, ability to fill defects of irregular shape, and capacity for delivering os-
teoinductive stimuli.
Materials and methods: In this study, we targeted these requirements by preparing a new com-
posite of b-tricalcium phosphate (TCP) and a thermoresponsive hyaluronan (HA) hydrogel.
Dissolution properties of the composite as a function of the particle size and polymeric phase
molecular weight and concentration were analysed to identify the best compositions.
Results: Owing to its amphiphilic character, the composite was able to provide controlled
release of both recombinant human bone morphogenetic protein-2 and dexamethasone,
selected as models for a biologic and a small hydrophobic molecule, respectively.
Conclusion: The TCPethermoresponsive HA hydrogel composite developed in this work can be
used for preparing synthetic bone substitutes in the form of injectable or mouldable pastes and
can be supplemented with small hydrophobic molecules or biologics for improved osteoinduc-
tivity.
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Biomaterials able to reduce or replace the need for autol-
ogous bone transplantation are a compelling need in
maxillofacial, orthopaedic, and reconstructive surgery [1].
In the context of an increasingly ageing global population
that is keen on maintaining an active lifestyle and expect-
ing improved life quality, this need is particularly urgent.
Nowadays, bone grafting is a very common practice, with
2.2 million procedures being performed annually [2]. Ex-
amples of grafting procedures include spinal fusions, limb
length restoration, bone reconstruction after tumour
resection, and maxillary sinus augmentation [3]. In all of
these and in similar cases, bone autografts are generally
recognized as more effective than off-the-shelf alterna-
tives; however, the autograft harvesting procedure is
associated with considerable risks and donor site pain and
morbidity, thereby lowering substantially the benefit-to-
risk ratio. Therefore, calcium phosphate (CaP)-based syn-
thetic bone graft substitutes are a valid alternative to au-
tografts and have been clinically used for this purpose for
many decades [4e6]. Despite the capacity of supporting
bone ingrowth from viable bone at the grafting site
(osteoconductivity), they generally do not induce bone
growth per se (osteoinductivity). CaP-based synthetic bone
graft substitutes are specifically produced with inter-
connected porosity, which facilitates body fluids perfusion,
cell invasion, and blood vessel ingrowth. In addition, the
surface chemistry of CaP is characterized by the presence
of charges from calcium and phosphate ions. This feature is
exploited in CaP-based drug delivery systems, particularly
for genetic material [7], growth factors [8], and antibiotics
[9]. For hydrophobic drug species, the ionic nature of the
underlying interactions is a limitation to the versatility of
CaP materials as drug delivery systems. Therefore, the
combination of CaP with matrices improving their versa-
tility as drug delivery systems is highly needed.
CaPs are generally supplied as granules of varying sizes. As
withmost ceramicmaterials, they are inherently brittle, and
their mechanical strength is additionally decreased by the
porosity. These are important limitations. In fact, a funda-
mental desirable characteristic of synthetic bone substitutes
is being easily shaped to adapt to an irregular bone defect
[10]. Ideally, the construct should therefore be sufficiently
soft and plastic. At the same time, the implant should not be
dislocated after adjacent tissue compression or body fluids
washout, and therefore it should maintain its cohesion after
implantation. This is often achieved by combining CaP par-
ticles and a polymeric matrix or a hydrogel [11e17].
Hydrogels are hydrated molecular networks well-known
for their capability of acting as drug reservoirs and facili-
tating controlled drug release [18,19]. Hydrogels act as
matrices, physically slowing down drug diffusion. More-
over, depending on their composition, they can establish
specific chemical interactions with the drug and thereby
modulate the drug release kinetics. Chemical affinity is
sometimes a limitation, as non-water-soluble drugs can be
difficult to incorporate into common hydrogels, which have
inherently high water content. In this case, liposomes or
micro/nanoparticles composites are generally used
[20e22].To target the needs of osteoconductivity, versatility,
improved handling and cohesion properties, and potential
drug delivery, we prepared a new combination of b-trical-
cium phosphate (TCP) granules with a thermoresponsive
hyaluronan (HA) matrix. In 2012, Tian et al [23] reported
the use of a thermoresponsive chitosan matrix for demin-
eralized bone matrix delivery. In our study, HA was selected
as the main component because it is fully biocompatible,
non-immunogenic, and readily available in medical grade.
HA is a natural component of the extracellular matrix
playing a key role in tissue repair [24,25]. Recently, HA was
demonstrated to improve the osteoconductive properties of
CaP [26]. In this study, HA was modified with pendant
moieties of thermoresponsive poly(N-isopropylacrylamide)
(pNIPAM) to obtain a co-polymer (HpN) that undergoes a
temperature-induced transition to a gel state. Importantly,
the transition takes place between room and body tem-
perature without covalent cross-linking and therefore in a
bio-orthogonal manner, that is, without interfering with
physiological biochemical processes.
In this study, we prepared an array of TCP/HpN com-
posites of varying TCP particle size, TCP concentration,
polymer phase concentration, and molecular weight of HA
within HpN and assessed their properties as potential syn-
thetic bone grafting materials. Handling properties were
determined through rheological and dissolution profiles and
composites were characterized via scanning electron mi-
croscopy (SEM) imaging and micro-computed tomography
(micro-CT). Selected composites were tested for their
ability to act as drug delivery vehicles. Release rates from
composites of recombinant human bone morphogenetic
protein-2 (rhBMP-2) and dexamethasone (DEX), which were
selected as models of a hydrophilic biological drug and a
small hydrophobic drug, respectively, were determined.
Finally, cytotoxicity against telomerase-immortalized
human foreskin fibroblasts was evaluated.Materials and methods
Materials
HA sodium salts from Streptococcus equi with weight-
average molecular weight of 1506 kDa [high molecular
weight (HMW)] and 280 kDa [low molecular weight (LMW)]
were purchased from Contipro Biotech s.r.o. (Dolni
Dobrouc, Czech Republic). Amino-terminated pNIPAM
(number-average molecular weight, 34 kDa) was purchased
from Polymer Source, Inc. (Dorval, Canada). ChronOS Beta-
TCP granules with different particle sizes were supplied by
DePuy Synthes USA Products LLC (West Chester, PA, USA),
rhBMP-2 (InductOs; Medtronic BioPharma B.V., Heerlen,
Netherlands) was purchased from Alloga AG (Burgdorf,
Switzerland); DEX was purchased from TCI Europe N.V.
(Zwijndrecht, Belgium); rhBMP-2 enzyme-linked immuno-
sorbent assay (ELISA) kit Duo Set from R&D Systems Inc.
(Minneapolis, MN, USA), and Cell Titer-Blue Cell Viability
Assay from Promega AG (Du¨bendorf, Switzerland). All other
reagents were purchased from SigmaeAldrich (Buchs,
Switzerland). Chemicals were of analytical grade at least,
and were used without further purification.
Hyaluronan hydrogel composite for drug delivery 59HpN synthesis and characterization
HpN was prepared by conjugating HMW or LMW HA with
amino-terminated pNIPAM via carbonyldiimidazole-
mediated amide formation according to a previously
described method [27] to give HHpN and LHpN,
respectively.
The reaction was carried out in dimethyl sulphoxide for 2
days at room temperature and the final product was puri-
fied by dialysis against demineralized water for 5 days. HpN
was freeze dried, desiccated under vacuum at 42C, and
stored at room temperature.
The molar degree of substitution (DSmol), defined as the
number of carboxyl groups functionalized with pNIPAM per
repeating unit of HA, was determined by 1H nuclear mag-
netic resonance (NMR) comparing the integrals of the peaks
of the non-anomeric protons of HA between 3.00 ppm and
3.77 ppm and the methyl group of the pNIPAM at 1.14 ppm.
Spectra were acquired on a Bruker AVANCE AV-500 MHz NMR
spectrometer. Deuterium oxide was used as a solvent and
the spectra were processed using Mnova version 9.0 soft-
ware (Mestrelab Research, Santiago de Compostela, A
Corun˜a, Spain).
Rheological measurements were performed using an
Anton Paar MCR-302 rheometer (Anton Paar GmbH, Baden-
Wurttemberg, Germany) equipped with a Peltier tempera-
ture control device. A 25-mm diameter cone-plate geom-
etry was used with a 0.049-mm gap, predetermined by the
geometry. The freeze-dried HpN was rehydrated with a
phosphate-buffered saline (PBS) solution (pH 7.4) at the
desired concentration (20% w/w or 10% w/w) until homo-
geneity was achieved. Oscillatory tests (amplitude, fre-
quency, and temperature sweep) were performed for each
HpN sample. The linear viscoelastic region was determined
using a strain sweep at a frequency of 1 Hz. A strain of 0.5%
was determined to be within the linear viscoelastic region
for all the HpN batches and was selected for all rheological
measurements. Temperature sweep was performed be-
tween 20C and 40C with a ramp rate of 1C/min at con-
stant amplitude (0.5%) and frequency (1 Hz). Low-viscosity
silicon oil was used at the meniscus interface to avoid
sample drying. Figure S1 online shows the temperature
sweep of 20% w/v HHpN solution.
TCP/HpN composite preparation
Composites were prepared with varying HpN polymer so-
lution concentration, molecular weight of HA within HpN,Table 1 Range of variation of concentration and charac-
teristics of the components within the composites.
HA MW HpN
solution
TCP
content
TCP granules size
range and notation
HMW
1.5 MDa
12% or 20%
w/v
40e80%
w/v
<0.25 mm b1
0.25e0.5 mm b2
LMW
0.28 MDa
0.5e0.7 mm b3
0.7e1.4 mm b4
HA Z hyaluronan; HMW Z high molecular weight; TCP Z b-
tricalcium phosphate; LMW Z low molecular weight.and CaP particle content and particle size. The range of
variation of each parameter is presented in Table 1. The
notation used throughout this manuscript to identify a
composition is as follows: the first character is either H or L,
identifying high or low molecular weight of HA; the first
number identifies the HpN concentration in % w/v; the
second number expresses the granules content in % w/v;
finally, b1, b2, b3, or b4 identifies the particle size ac-
cording to Table 1. For example, the composition H20-75b4
is prepared from a 20% w/v HMW HpN solution and 75% w/v
of TCP granules with a 0.7e0.14-mm size. As control,
composites using pure HMW HA as polymeric phase were
prepared.
To prepare the composites, lyophilized HpN and TCP
particles were weighed; to this, PBS solution was added and
all the components were mixed with a spatula for few mi-
nutes until a homogeneous paste was obtained.
SEM imaging and micro-CT
A 100-mg bead of H20-40b2 composite was prepared,
frozen in liquid nitrogen, and lyophilized. The dehydrated
bead was fractured, coated with 10 nm of carbon and
imaged with a Hitachi S-4700 II field emission scanning
electron microscope (Hitachi High-Technologies Europe
GmbH, Krefeld, Germany) at 5-kV accelerating voltage.
Images were taken in the secondary electron mode. In
addition, the elemental analysis of the material at the TCP/
HpN interface was evaluated by energy-dispersive X-ray
spectroscopy (EDX, INCA V5.2; Oxford Instruments plc,
Oxfordshire, UK) with the accelerating voltage at 10 kV.
Three H20-40b1 composite beads were scanned using a
mCT40 (Scanco Medical AG, Bru¨ttisellen, Switzerland) with
a resolution (voxel size) of 12 mm (70 kVp, 114 mA, and
150 ms integration time). A three-dimensional segmenta-
tion followed by a morphometric analysis was performed
for the whole bead. Three spatial regions of the bead
(upper, middle, and lower) consisting of 40 slices each were
identified and quantitative information about the granules
particle size and the distance between them were
obtained.
Dissolution and injectability tests
Dissolution test
The dissolution test consists of evaluating the shape main-
tenance after immersion into a PBS solution at 37C. The
composite was formed into a bead and placed into a 20-mL
vial filled with PBS solution at 37C. Composites with TCP
particles of size below 0.5 mm were loaded into a 1-mL
syringe and extruded into a 20-mL vial filled with PBS so-
lution at 37C. Pictures were taken immediately after
extrusion and every fifth day for 25 days.
Injectability test
Injectability of selected composites was quantitatively
measured with an Instron 4302 electromechanical testing
machine in compression configuration. A 0.4-mL volume of
composite was placed in a 1-mL syringe with a round-tip
opening of 2.1 mm inner diameter. Syringes were mounted
vertically in a custom-made stand. A load cell of 50 N was
60 D. Petta et al.used. The compressive curve was registered at a cross-head
speed of 120 mm/min. Results are reported as the average
of three replicas.rhBMP-2 and DEX release
Freeze-dried HHpN and b1 TCP granules were mixed
together; a 0.1% bovine serum albumin (BSA) solution con-
taining the drug was added and the components were
mixed with a spatula for a few minutes. The formulation
was shaped as a bead with a final weight of 100 mg. Beads
containing rhBMP-2 (5 mg/bead) or DEX (100 mg/bead) were
prepared. Control groups were HHpN bead only and TCP
granules (b1) only. All control groups were loaded with the
same amount of rhBMP-2 or DEX as the test samples. Sam-
ples were prepared in triplicate. Additional groups with a
solution of pure rhBMP-2 or DEX were also included.
In vitro rhBMP-2 release
rhBMP-2 was supplied as a lyophilized powder in a formu-
lation buffer containing 2.5% glycine, 0.5% sucrose, 0.01%
polysorbate 80, 5mM sodium chloride, and 5mM L-glutamic
acid. The protein was reconstituted to a final concentration
of 1.5 mg/mL in a 0.1% BSA solution in PBS and then with
the formulation buffer supplemented with 0.1% BSA, to a
final concentration of 500 mg/mL. For the release study,
10 mL of this solution was added to the polymeric phase
during the preparation of the composite bead to load each
sample with 5 mg of rhBMP-2. A release experiment was
performed under the same conditions except for loading
the growth factor in the inorganic phase. The release of
rhBMP-2 from the composite was determined by placing
each composite bead in 1 mL of release buffer (PBS þ 0.1%
BSA þ 0.05% sodium azide) in low protein-binding Eppen-
dorf tubes at 37C under mild agitation (10 rpm). At
different time points (1 hour, 3 hours, 8 hours, 1 day, 2
days, 3 days, 5 days, 8 days, and 13 days), 100 mL of release
buffer was withdrawn and replaced with the same amount
of fresh buffer. Samples were stored at 20C until ELISA
analysis. The ELISA was run after appropriate dilution
following the protocol provided by the supplier and the
final absorbance was measured at 450 nm and corrected
with the reading at 540 nm for optical compensation. The
concentration of rhBMP-2 released from the different
samples was normalized to the actual rhBMP-2 detected in
the control group (5 mg of rhBMP-2 in release buffer). The
tested items were prepared in triplicate and each replica
was run in duplicate for the ELISA. Final concentrations
were calculated according to the dilution at every time
point.
Sodium dodecyl sulphate-polyacrylamide gel
electrophoresis
Sodium dodecyl sulphate-polyacrylamide gel electropho-
resis (SDS-PAGE) was performed to detect the rhBMP-2 that
was not released from the TCP granules. Samples analysed
were as follows: (1) 5 mg/mL rhBMP-2 as control, recon-
stituted with or without 0.1% BSA and (2) TCP granules
loaded with 5 mg of rhBMP-2 after 13 days of incubation in
release media.Samples (1) and (2) were tested under reducing (b-
mercaptoethanol) and nonreducing conditions by incu-
bating for 5 minutes at 95C in Laemmli buffer, consisting of
62.5mM TriseHCl (pH 6.8), 25% glycerol, 2% SDS, and 0.01%
bromophenol blue. TCP granules from Sample (2) were
removed from the release media before addition to the
Laemmli buffer. Samples were loaded on a 15% gel and the
electrophoresis was run at 100 V for 20 minutes and then at
80 V for an additional 1 hour and 30 minutes. The gel was
stained with a coomassie blue G-250 for 20 minutes (coo-
massie blue 0.3% þ acetic acid 10% þ methanol 25%) and
destained in methanol/acetic acid solution (25%
methanol þ 10% acetic acid). Destained gels were visual-
ized using the ChemiGenius Bioimaging System (Syngene, A
Division of Synoptics Ltd, Cambridge, United Kingdom).
In vitro DEX release
DEX was freshly reconstituted with ethanol to a concentra-
tion of 5mg/mL. DEX solution (20 mL) was loaded onto TCP b1
granules. The solvent was allowed to evaporate at room
temperature and HpN þ PBS was added to obtain 100 mg of
DEX for each bead. For the release study, each composite
bead was incubated at 37C under mild agitation conditions
in 1.5mL of release buffer. The releasewas carried out for 13
days and for each time point, 300 mL of release buffer was
removed and replaced with fresh buffer. Collected samples
were stored at 4C until analysis. DEXwas quantified by high-
performance liquid chromatography on a Kinetex 5-mm C18
100A column (Phenomenex Inc., Torrance, CA, USA) with
triamcinolone acetonide as internal standard [28]. Mobile
phase was acetonitrile:water 28:72, pH 2.3, at a flow rate of
1.2mL/min and thedetectorwavelengthwas 241 nm. In a set
of six replicates of the same sample, a standard deviation of
1.6% was found (data not shown). The linearity of the DEX
was between 0.35 mg/mL and 12.5 mg/mL. Final concentra-
tions were calculated according to the dilution at every time
point. Furthermore, the specimens were allowed to release
for up to 3 months, following which they demonstrated no
further release (data not shown).
Reconstitution time of dry formulations
Reconstitution of the formulation H20-40b1 was performed
using two different protocols, identified as A and B. In
Protocol A (see Video S1 online), the ceramic and the
polymeric phase of the composite were mixed and rehy-
drated with a 500 mg/mL rhBMP-2 solution. In Protocol B,
the composite was prehydrated with a 500 mg/mL rhBMP-2
solution and weighed. MilliQ water was added, which re-
sults in a threefold weight increase. The bead was smashed
with a spatula and freeze dried. Finally, the freeze-dried
composite formulation was reconstituted to its original
volume (before swelling to the threefold weight increase)
with MilliQ water (see Video S2 online). For both Protocols A
and B, the reconstituted material had the following
composition: 98 mg of TCP granules (b1), 50.4 mg of HpN,
35 mL of rhBMP-2 solution (500 mg/mL), and 217 mL of PBS
solution. For both protocols, reconstitution was performed
in a plastic vessel by mixing manually with a spatula.
Supplementary data related to this article can be found
online at http://dx.doi.org/10.1016/j.jot.2015.11.001.
Figure 1 Storage modulus G0 against the temperature of 20%
w/v (black line) and 10% w/v (red dashed line) HHpN and 20%
w/v (green dotted line) and 10% w/v (blue dashedot line) LHpN
solutions.
Hyaluronan hydrogel composite for drug delivery 61Cytotoxicity assay of the composite formulation
Cytotoxicity was evaluated by assessing the viability of
telomerase-immortalized human foreskin (hTERT-BJ1) fi-
broblasts after contact with extracts of composite beads. A
CellTiter-Blue Cell Viability Assay (Promega AG) was per-
formed in conformity to the ISO STANDARD 10993-5. The
tested substances were sterilized with cold ethylene oxide.
All the samples were incubated for 24 hours in 2.5 mL of
extraction vehicle at 37C, that is, culture medium sup-
plemented with 5% foetal calf serum and either 0.5 g of the
composited15 cm2 of the positive control (latex)dorFigure 2 Scanning electron microscopy images of an H20-40b2 b
and the bulk of the bead, where a b-tricalcium phosphate (TCP) g
another area within the same specimen. The white rectangular fra
hydrogel within a TCP pore. The white triangle on the TCP and circle
energy-dispersive X-ray spectroscopy spectra in panel (D) were acq7.5 cm2 of the negative control (high-density poly-
ethylene). hTERT-BJ1 fibroblasts were seeded in 96-well
plates at a density of 2000 cells/100 mL of culture me-
dium (Dulbecco’s modified Eagle’s medium supplied with 5%
foetal calf serum) in a 96-well plate and incubated for 24
hours at 37C, 5% CO2, 95% humidity. The medium was then
removed from each well and 100 mL of the different
extraction media from the test items were added to each
well in triplicate. On Days 1 and 3, the extraction medium
was removed and cells were incubated with a 10% CellTiter-
Blue solution for 2.5 hours. The fluorescence signal was
read using a VICTOR3 Perkin Elmer plate reader (Perkin
Elmer Inc., Waltham, MA, USA). All fluorescence values
were normalized to the fluorescence value of the cells
seeded in the presence of culture medium at Day 1 and Day
3.Results
Characterization of the co-polymer
HpN co-polymers with different rheological properties were
synthesized according to protocols already established [27].
DSmol of HpN was consistently 5% of the carboxyl groups
functionalized, corresponding to about 9 mol of pNIPAM/
mole of HA repeating unit. The temperature dependence of
the storage modulus of HpN solutions of high and low mo-
lecular weight at 10% w/v and 20% w/v concentration is
shown in Figure 1. LHpN at 10%w/v showed a sharp transitionead cross section. (A) Interface between the external surface
ranule completely embedded in hydrogel is visible. (B) Bulk of
me is magnified in panel (C), where the white arrow indicates
on the hydrogel in panel (B) represent the focal regions where
uired. All scale bars correspond to 50 mm.
62 D. Petta et al.around 29C, with the storage modulus increasing over two
orders of magnitude between room temperature and physi-
ological temperature. At 20% w/v concentration, the LHpN
storage modulus was 10-fold higher than LHpN at 10% w/v
and showed a fivefold increase as the temperature was
increased from room temperature to physiological temper-
ature with a slight decrease in the transition temperature at
the higher concentration. G0 of HHpN was markedly higher
than LHpN at room temperature at both 10% w/v and 20% w/
v, and the transition amplitude was smaller, especially for
HHpN 10% w/v.
An evaluation of the formulation stability of 20% w/v
HHpN was carried out by measuring the rheological profile
at different time points out to 11 weeks. Results in Figure
S1 online show how the temperature-induced solegel
transition and viscoelastic shear moduli values were
maintained.
SEM and micro-CT imaging of the composites
Figure 2A shows the cross section of a fractured bead of the
composite H20-40b2. The external surface of the bead in
the upper part of the image is visible as a smooth layer,
under which the dried hydrogel shows a porosity of char-
acteristic size around 5 mm. A TCP granule embedded in the
hydrogel matrix is clearly visible as a denser and brighterFigure 3 Micro-computed tomography scan of the H20-40b1 c
section; (B) size distribution of the b-tricalcium phosphate (TCP) gr
the thickness in mm); (C) distribution of the particle size after a
distribution of the TCP granules (the gradient colour bar indicate
rectangles indicate the three analysed regions, namely, upper (U),area. Figures 2B and 2C represent another area from the
same sample. The gapless contact between the hydrogel
and the ceramic surface is obvious, with the hydrogel filling
the macroporosity as well as the microporosity within the
TCP granules (Figure 2C and Figure S2). Results of EDX
spectroscopy showed the presence of carbon, oxygen,
phosphorus, and calcium for the mineral part and carbon,
oxygen, sodium, and chloride for the hydrogel part
(Figure 2D).
The three-dimensional segmentation analysis from
micro-CT imaging confirmed the uniform distribution of TCP
granules within the HpN polymeric matrix, both on the
surface and inside the bead, as shown in Figure 3A.
The morphometric analysis for the whole volume of the
bead (Figure 3B) displayed a Gaussian distribution of the
granules size, expressed as particle thickness (Figure 3C).
Furthermore, the mean granules distance (Figure 3D) in the
three different regions U, M, and L was 0.225 mm,
0.209 mm, and 0.197 mm, respectively (standard deviation
6.63%).
Dissolution and injectability test
The results of the dissolution test of formulations prepared
with varying content of hydrogel and inorganic phase are
reported in Table 2.omposite. (A) Three-dimensional reconstruction of half bead
anules within the composite (the gradient colour bar indicates
two-point fast Fourier transform filter smoothing; (D) spatial
s the distance between the granules in mm, the red dashed
middle (M), and lower (L). Scale bars Z 1 mm.
Table 2 Outcome of the dissolution test.
Abbreviation Dissolution test
HA HMW 20% þ 60% b3 Not passed
H20-40b1 Passed
H20-40b2 Passed
H20-40b3 Passed
H20-40b4 Passed
H20-60b3 Passed
H20-80b3 Passed
H20-80b4 Passed
L12-50b3 Not passed
L12-60b3 Not passed
L12-80b1 Not passed
L12-75b2 Not passed
L12-80b3 Partially passed
L20-40b1 Partially passed
L20-40b2 Partially passed
L20-40b3 Partially passed
L20-60b3 Partially passed
L20-80b3 Partially passed
L20-40b4 Passed
L20-60b4 Passed
L20-80b4 Passed
Nomenclature of abbreviations in Table 2 is explained in the
“TCP/HpN Composite Preparation” section.
HA Z hyaluronan; HMW Z high molecular weight.
Figure 5 Cumulative release of recombinant human bone
morphogenetic protein-2 (rhBMP-2) from the H20-40b1 com-
posite (red solid line), from HHpN (blue dotted line), and from
b-tricalcium phosphate (TCP) granules (black dashed line).
Values are normalized to the total loaded. The lines represent
the average of three replicas and the bars the standard
deviation.
Hyaluronan hydrogel composite for drug delivery 63Putties prepared from HHpN at 20% w/v (H20-40b1, H20-
40b2, etc.) passed the dissolution test for each granule size
and concentration of mineral phase tested. These com-
posites displayed shape maintenance, no turbidity, and no
crumbling of the particles for 25 days, as shown in
Figure 4B. These samples were stored for 8 months in the
same conditions and showed no visible changes (data not
shown). The putty prepared from pristine HMW HA at the
same concentration (first row in Table 2) disintegratedFigure 4 Dissolution test for the composites. (A) L20-40b1 at time
days.completely after dissolution testing (see Figure S3 online).
Dissolution tests of LHpN putties gave results dependent on
both polymer concentration and particle size. Formulations
prepared from LHpN at 12% w/v showed a relatively low
viscosity for paste preparation and gave negative outcome
for all particles content, except for the dissolution test of
the sample L12-80b3, where the shape was maintained and
only a few particles detached (see Figure S4 online).
Therefore, for this sample, a partial pass was attributed.
Increasing the LHpN concentration to 20%, w/v formula-
tions showed a visible shape collapse in the dissolution test
(see Figure S5 online). Because the basic shape was main-
tained and very minor particle crumbling was observed, this
was considered a partial pass (Figure 4A). Putties prepared
from b4 particles (size 0.7e1.4 mm) and LHpN 20% w/v,
fully passed the test.(t) 0 days and 5 days and (B) H20-40b1 at time (t) 0 days and 25
Figure 6 Sodium dodecyl sulphate-polyacrylamide gel elec-
trophoresis of recombinant human bone morphogenetic
protein-2 (rhBMP-2) reconstituted in the presence (Lanes III
and V) or absence (Lanes II and IV) of b-mercaptoethanol. Lane
VI contains b-tricalcium phosphate (TCP) granules loaded with
5 mg of rhBMP-2; Lane I corresponds to the markers solution
(Precision Plus Protein Western C Standard). BSA Z bovine
serum albumin.
64 D. Petta et al.Injectability
The extrusion of the composites with granules of size above
0.5 mm led to the creation of a composition gradient with
the extruded part enriched in polymeric phase and smaller
particles, and the retained material enriched in the TCP
solid phase. This phenomenon is known as filter pressing,
phase migration, or phase separation [29e31]. Composi-
tions with particles below 0.5 mm were extruded without
visually observable filter pressing. Based on this outcome,
only composites containing TCP granules of particle size
below 0.5 mm were further developed as injectable
formulations.
A quantitative injectability testing was performed in
triplicate for the H20-40b2 formulation, prepared from theFigure 7 Curves of cumulative release of dexamethasone
(DEX) from the H20-40b1 composite (dashed red line), from
HHpN (dotted blue line), and from b1-TCP (solid black line).
The data represent the average of three replicas and the bars
the standard deviation. TCP Z b-tricalcium phosphate.highest concentration of the HMW polymer with the biggest
particle size suitable for injection. The forceedisplace-
ment profiles were characterized by a rapid increase of the
force at the beginning of the extrusion and a transition to a
smooth plateau phase (see Figure S6 online). The extrusion
force is in a very low range for the investigated formula-
tion, with a plateau around 4 N.
rhBMP-2 release
In Figure 5, the release profile of rhBMP-2 is displayed. Pure
HHpN hydrogel (blue dotted line) released most of the
available rhBMP-2 in the first 3 days. TCP granules displayed
a burst release achieving most of the amount obtainable
over the 300-hour period released within the first 6 hours
(black dashed line). For the H20-40b1 composite, the
release was more controlled, with lower amounts released
for each time point (red solid line) compared with either
TCP granules or HpN. The fraction of rhBMP-2 released over
the study compared with the nominal loaded amount was
45% for HHpN, 30% for TCP b-1, and 10% for the composite.
rhBMP-2 remaining on the TCP particles after the release
study was analysed via SDS-PAGE. In Figure 6, Lanes IIeV
are rhBMP-2 at 5 mg/mL, whereas Lane VI represents the
analysis of the TCP particles after the release study. rhBMP-
2 under nonreducing conditions (Lane II) gave a band at
molecular weight of approximately 30 kDa, as expected. In
reducing conditions (Lane III), rhBMP-2 was split into two
major subunits of approximately 15 kDa. In Lanes IV
(nonreducing) and V (reducing), the same analysis was
performed in the presence of BSA, confirming the previous
results and showing an intense band from BSA at approxi-
mately 66 kDa, as expected. The analysis of the TCP par-
ticles under reducing conditions after extraction for 13 days
(Lane VI) clearly demonstrated the split of rhBMP-2 into its
monomeric units. BSA was not detectable for this sample.
Reconstitution of dry formulations
Reconstitution of the dry formulations was performed to
obtain composites containing rhBMP-2, and is shown in
Supplementary Videos S1 and S2 online for Protocols A
(reconstitution with rhBMP-2 solution) and B (reconstitution
with water, rhBMP-2 included in the dry phase), respec-
tively. Regardless of the protocols used, after around 1.5
minutes, the formulation reached a grade of homogeneity
sufficient for further use and could be handled and shaped
as a bead. A small amount of adhesion of the composite to
the plastic vessel was noted.
DEX release
Figure 7 compares the release of DEX from the H20-40b1
composite and from its components TCP (b1) and HHpN.
TCP released 38% of DEX after 3 hours and 53% after 6
hours. HHpN and H20-40b1 did not display such a substan-
tial burst, with 44% and 29% released at 6 hours, respec-
tively. The composite exhibited a lower burst release and a
more gradual extended release compared with HHpN. At
the end of the study, 47% of the loaded DEX was released
from H20-40b1. Compared with rhBMP-2, for both HpN and
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compared with the DEX release. At 24 hours, TCP particles
released 90% of DEX. In the same conditions, rhBMP-2 was
released to an amount of 28% of the total load. For both
rhBMP-2 and DEX, the amount released after 24 hours fol-
lowed the order TCP > HHpN > composite.
Cytotoxicity
At 24 hours, the H20-40b2 composite extract showed a
cytotoxicity of 25%; after 72 hours the cytotoxicity was 19%.
Extracts of TCP granules alone were not cytotoxic at any
time point (Figure 8). According to the ISO 10993e5:2009
standard, the threshold deemed cytotoxic is viability below
70%, or cytotoxicity above 30%. The polyethylene extract at
72 hours gave fluorescence signal higher than the control
(hTERT-BJ1 þ medium), which indicates a possible prolif-
eration of the cells in these conditions.
Discussion
Characterization and general properties
Chemical modification of HA with amphiphilic moieties of
pNIPAM provides this semisynthetic derivative with the
singular feature of inducing a sharp transition to a gel state
and an increase of viscoelastic shear moduli of more than
two orders of magnitude within a narrow temperature in-
terval. The reciprocal influence of the molecular weight of
the polymeric components, relative degree of substitution,
and concentration were previously analysed [32]; the sys-
tem was optimized for a sharp transition and negligible
shrinking [33].
In this study, we prepared and characterized a wide
spectrum of composites of varying molecular weight of HAFigure 8 Values of fluorescence obtained from alamarBlue
assay for pure extracts of the composite H20-40b2, b-trical-
cium phosphate (TCP) granules, and hyaluronan (HA) after in-
cubation of hTERT-BJ1 fibroblasts with extraction medium at
24 hours (white bars) and 72 hours (dark bars), respectively. PC
and PE represent, respectively, the positive control (latex) and
the negative control (high-density polyethylene). The error
bars represent the standard deviation in percentage calculated
on a number of three repeats.within HpN, total concentration of polymer, total content
of TCP particles, and TCP particle size. Composites were
characterized for their shape retention after incubation in
buffer. This testing is designed to challenge the composite’s
capability of holding together in humid environment and
thereby mimic the conditions after implantation. Pristine
HA is known for its extremely high hydrophilicity. There-
fore, the composite prepared from pure HA (HA HMW
20% þ 60% b3, control) was easily swollen in water and fell
apart during dissolution testing. By contrast, composites
prepared from 20% w/v HHpN were able to maintain their
shape owing to the underlying molecular network and gel
properties. The LHpN solution at 12% w/v concentration did
not have adequate cohesiveness and at least a 20% w/v
concentration of the polymer in the composite was
required for displaying some degree of shape retention.
This was expected, because for the polymer to act as a
binder for the particles, it must be sufficiently viscous. For
the same reason, HHpN gives better performance compared
with the LHpN. Temperature sweep analysis shows that
HHpN displays higher moduli at both room and body tem-
perature. Specifically, the increased viscosity at room
temperature gives a better initial cohesion to the com-
posite and makes it more easily handled. Formulations
prepared from 20% w/v LHpN had rheological properties
barely sufficient to bind the particles, and therefore the
outcome of the dissolution test was particle size depen-
dent, with only the bigger particles giving satisfactory
cohesion. Micro-CT analysis is a powerful tool for evaluating
particle size and distribution within the composites. Parti-
cle size analysis confirmed the expected dimension,
revealing no particle coalescence. Particle distribution was
relatively uniform throughout the bead with no evidence of
significant sedimentation. SEM images show a gapless con-
tact between the ceramic granules and the polymeric ma-
trix, with the hydrogel penetrating the microporosity
(Figure 2C and Figure S2 online). The local composition
assessed by EDX analysis confirmed the identification of the
components. The carbon in the bioceramic part arises from
the carbon coating, whereas chlorine results from the PBS
as solvent for the HpN. The sodium is derived from both the
PBS and as counterion for the carboxyl groups of HA.
Intuitively, improving the cohesion of a formulation
works to the detriment of injectability. It is known that the
force versus displacement curves characterize the extru-
sion process and depend on syringe size and type, plunger
displacement speed, material and gauge of cannula as well
as the rheological properties of the ceramic particles [11].
The extrusion test showed that the composites H20-40b1
and H20-40b2 can be extruded from an insulin syringe
with a very little force and without phase separation,
whereas formulations with granules above 0.5 mm exhibit
filter pressing. Therefore, the composites with particle size
below 0.5 mm are suitable for the preparation of both
mouldable putties and injectable formulations, whereas
composites with particle size above 0.5 mm are suitable for
the preparation of mouldable putties. The form in which a
composite biomaterial is provided to the surgeon is
important for its clinical performance [34]. The HpN co-
polymer maintains its temperature-induced gel-formation
performance for at least 11 weeks upon storage in solution
at 4C. This stability allows the preparation of the
66 D. Petta et al.composites as off-the-shelf prehydrated formulations. As
shown in the Supplementary Videos S1 and S2 online,
rehydration of the dry form immediately before use is also
possible within a time span conveniently compatible with
surgical procedures. Therefore, the composites presented
in this study are suitable for the preparation of both pre-
hydrated and to-be-reconstituted formulations.
The degradation profile of the composites here pre-
sented is governed by the degradation of its components.
For TCP, the resorption is mainly cell mediated [35]. The
polymeric carrier is subject to enzymatic degradation
in vitro [33] and in vivo [36]. Therefore, the degree of
chemical modification on HA in the thermoresponsive gel is
such that the derivative is still recognized by hyaluroni-
dase, which is indicative of preservation of HA biological
activity. Unlike HA, pNIPAM is not biodegradable. However,
in vivo it is eliminated via urinary excretion [37]. This fate
is similar to polyethylene glycol, which is widely used in
biomaterials and pharmaceutical preparations for paren-
teral use [38].rhBMP-2 and DEX release
Ideally, biomaterial-based delivery systems are intended to
enhance the natural tissue response by supplying adequate
biochemical cues. Bone healing entails a complex cascade
of events, progressing under the regulation of different
small and biological molecules. In this study, we selected
rhBMP-2 and DEX as model molecules to deliver. rhBMP-2 is
a water-soluble full-size protein of molecular weight 30 kDa
and an isoelectric point of approximately 9 and is well-
known for its bone-inducing properties [39,40]. rhBMP-2
delivered in absorbable collagen sponge is already
approved for clinical use in spine fusions [41] and tibial
fractures [42]. DEX (molecular weight Z 392.46 Da) is a
non-water-soluble synthetic steroidal anti-inflammatory
drug that was selected as a model for small hydrophobic
molecule. Although typically used in cell culture as
component of osteogenic media, DEX is not clinically used
for bone growth. The molecules selected have different
physicochemical properties, and were deemed suitable for
assessing the versatility of a delivery system. Based on the
injectability, the composite H20-40b1 was selected for
performing rhBMP-2 and DEX release studies.
To accomplish its therapeutic action, rhBMP-2 needs to
be released at the appropriate dose and time [43]. The
potency of rhBMP-2 in inducing bone is well recognized, but
after years of clinical use, serious issues of efficacy and
safety have been posed [44e46]. Most of these issues arise
from a suboptimal delivery system, which releases high
doses of rhBMP-2 over a short period. The composite pre-
sented in this study was effective in slowing down the
release of rhBMP-2, as shown in Figure 5, compared with
HpN or TCP alone. The dose of rhBMP-2 released was pre-
viously demonstrated to be effective in inducing bone
regeneration in vivo without ectopic bone formation or
other side effects [47]. The comparison of rhBMP-2 and DEX
release highlights that (1) TCP releases almost immediately
most of the 100 mg of DEX loaded, whereas only 30% of the
5 mg of rhBMP-2 loaded is released with a quasi-zero-order
kinetics; (2) HHpN and H20-40b1 show similar releasekinetics for DEX, but a quite different profile for rhBMP-2,
for which HHpN reaches plateau after 3 days, but the
composite displays a more gradual release; and (3) the total
and relative amounts released over the study are higher for
DEX. These differences emphasize how the release is
molecule dependent. The affinity of rhBMP-2 for CaP sur-
faces is known [48,49]. rhBMP-2 was still detectable on the
TCP particles after the release study through SDS-PAGE.
Interestingly, BSA, which was present in significant
amount in the release medium, was not detected on the
particles, indicating specificity of the TCPeproteins inter-
action. The high retention of rhBMP-2 observed for the
HpN/TCP composite is not expected after implantation
in vivo. In vitro release models do not mimic the tissue
environment, body movements generating mechanical
forces, blood and lymphatic circulation, the enzymatic
degradation or the action of inflammatory cells, and the
resorption of TCP by osteoclasts. Therefore, in vivo the
total amount of rhBMP-2 released is expected to be closer
to the loaded dose, as previously reported [20]. A limitation
of this study is that the biological activity of BMP-2 after
the release was not assessed. However, BMP-2 was identi-
fied via ELISA. If the BMP-2 structure was compromised
during encapsulation and release, BMP-2 would not be able
to present the epitope to the ELISA. Therefore, the posi-
tivity of the released BMP-2 to ELISA is an indication of
structure preservation. The optimal pharmacokinetic of
rhBMP-2 can only be determined in an in vivomodel, and its
determination needs to be investigated in future studies
[50].
In contrast to rhBMP-2, DEX shows low affinity to the
mineral phase and its release from TCP is quantitative,
whereas HpN retains 40% of DEX. The combination of TCP
with HpN induces a more gradual release (Figure 7). In our
model, the release of DEX is at least in part due to disso-
lution, as its concentration is above the solubility
threshold. Similar to TCP, HA is hydrophilic and scarcely
suitable to generate hydrophobic interactions capable of
modulating the release of hydrophobic species like DEX.
However, in our research, we used HA modified with moi-
eties of pNIPAM. Therefore, the use of a carrier constituted
by HA chemically modified with pNIPAM provides two
fundamental benefits: (1) providing the property of
temperature-induced gelation, which gives good inject-
ability but at the same time no dissolution in physiological
conditions, as verified via dissolution test and (2) intro-
ducing hydrophobic domains into the HA backbone; besides
forming a molecular network at body temperature, these
hydrophobic domains can interact with hydrophobic species
like DEX modulating its release. Understanding the associ-
ation of drug molecule with composite components, as well
as the effect of polymer and inorganic ratios and properties
on drug incorporation and release provides the option for
tailored drug delivery based on clinical need.Conclusion
In this study, we introduced a new synthetic bone substi-
tute composed of TCP and a thermoresponsive HA hydrogel.
The co-polymer has a low degree of derivatization, and
therefore it should be readily recognized as natural
Hyaluronan hydrogel composite for drug delivery 67extracellular matrix component by the host tissue. Owing
to the temperature-induced solegel transition of the soft
polymeric phase, handling properties are superior
compared with pristine HA composites in terms of cohesion
and dissolution. The composite displays good cohesion in
aqueous solution at physiological temperature and osmo-
larity, indicating the capability of filling defects of irregular
shape without washing out. Depending on the particle size,
putty or injectable formulations can be prepared. rhBMP-2
and DEX were selected as models of hydrophilic full-size
protein and small hydrophobic molecule to be released
from the composite, demonstrating the possibility of
releasing a wide range of molecules in a controlled manner.
The composite contains ionically charged surfaces, hydro-
philic, and amphiphilic functional groups. The interaction
of these microdomains with a drug will result in different
release characteristics for different molecules. For rhBMP-
2, the strong interaction with the bioceramic results in a
slower release and at the same time a lower overall re-
covery in vitro, compared with DEX. The capability of
releasing drugs of different nature in a controlled manner is
relevant towards the translation of synthetic bone graft
substitutes in clinical use. Bone grafting is used in a variety
of clinical situations, including, for example, bone recon-
struction after trauma, deformity or tumour resection,
sinus augmentation after tooth extraction, or spinal fusion
in elderly or younger patients. A versatile off-the-shelf
synthetic graft could be supplemented by the surgeon
with different drugs, for example, angiogenic stimuli,
osteoinductive stimuli, anti-inflammatory, analgesic, anti-
biotic, anticancer drugs depending on the clinical neces-
sity. The composite can be supplied as both a dry
formulation to be reconstituted perioperatively or as a
ready-to-use paste. Owing to its handling, cohesion, resis-
tance to washout, drug-delivery properties, and cyto-
compatibility, HpN/TCP composites are promising
substitutes for autologous bone transplantation in ortho-
paedics, dentistry, and trauma.Conflicts of interest
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